European Companies Search Engine
EU funding (€5,980,435): Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients Hor5 May 2015 EU Research and Innovation programme "Horizon"
Overview
Text
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Association Genethon - EU funding (€5,980,435): Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
